.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 7,005,122

« Back to Dashboard

Details for Patent: 7,005,122

Title:Delivery of sumatriptan, frovatriptan or naratriptan through an inhalation route
Abstract: The present invention relates to the delivery of anti-migraine compounds through an inhalation route. Specifically, it relates to aerosols containing sumatriptan, frovatriptan, or naratriptan that are used in inhalation therapy. In a method aspect of the present invention, sumatriptan, frovatriptan, or naratriptan is administered to a patient through an inhalation route. The method comprises: a) heating a thin layer of sumatriptan, frovatriptan, or naratriptan on a solid support to form a vapor; and, b) passing air through the heated vapor to produce aerosol particles having less than 5% drug degradation products. In a kit aspect of the present invention, a kit for delivering sumatriptan, frovatriptan, or naratriptan through an inhalation route is provided which comprises: a) a thin coating of a sumatriptan, frovatriptan, or naratriptan composition; and, b) a device for dispending said thin coating as a condensation aerosol.
Inventor(s): Hale; Ron L. (Woodside, CA), Rabinowitz; Joshua D. (Mountain View, CA), Solas; Dennis W. (San Francisco, CA), Zaffaroni; Alejandro C. (Atherton, CA)
Assignee: Alexza Pharmaceutical, Inc. (Palo Alto, CA)
Filing Date:Mar 03, 2004
Application Number:10/791,915
Claims:1. A dose form of sumatriptan comprising a condensation aerosol formed by heating a thin layer containing sumatriptan, on a solid support, to produce a vapor of sumatriptan and condensing the vapor to form a condensation aerosol characterized by less than 10% sumatriptan degradation products by weight, and an MMAD of less than 5 microns, wherein the dose form comprises less than 20 mg of sumatriptan.

2. A dose form of frovatriptan comprising a condensation aerosol formed by heating a thin layer containing frovatriptan, on a solid support, to produce a vapor of frovatriptan and condensing the vapor to form a condensation aerosol characterized by less than 10% frovatriptan degradation products by weight, and MMAD of less than 5 microns, wherein the dose form comprises less than 2 mg of frovatriptan.

3. A dose form of naratriptan comprising of a condensation aerosol formed heating a thin layer containing naratriptan, on a solid support, to produce a vapor of naratriptan and condensing the vapor to form a condensation aerosol characterized by less than 10% naratriptan degradation products by weight, and an MMAD of less than 5 microns, wherein the dose form comprises less than 0.8 mg of naratriptan.

4. A method of producing a dose form of sumatriptan comprising a condensation aerosol, the method comprising: a. heating a thin layer containing sumatriptan, on a solid support, to produce a vapor of sumatriptan, and b. providing an air flow through the vapor to form a condensation aerosol characterized by less than 10% sumatriptan degradation products by weight, and an MMAD of less than 5 microns, wherein the dose form comprises less than 20 mg of sumatriptan.

5. A method of producing a dose form of frovatriptan comprising a condensation aerosol, the method comprising: a. heating a thin layer containing frovatriptan, on a solid support, to produce a vapor of frovatriptan, and b. providing an air flow through the vapor to form a condensation aerosol characterized by less than 10% frovatriptan degradation products by weight, and an MMAD of less than 5 microns, wherein the dose form comprises less than 2 mg of frovatriptan.

6. A method of producing a dose form of naratriptan comprising a condensation aerosol, the method form comprising: a. heating a thin layer containing naratriptan on a solid support, to produce a vapor of naratriptan, and b. providing an air flow through the vapor to form a condensation aerosol characterized by less than 10% naratriptan degradation products by weight, and an MMAD of less than 5 microns, wherein the dose form comprises less than 0.8 mg of naratriptan.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc